Skip to main content

Table 2 Treatments and outcomes of patients (n = 24)

From: Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study

Clinical course Received CP (n = 14) Without CP (n = 10) P value
Treatments
 Antiviral, n (%) 14 (100) 10 (100) 1
 Glucocorticoids, n (%) 14 (100) 10 (100) 1
 Antibiotics, n (%) 9 (64) 3 (30) 0.213
 Antifungal, n (%) 6 (43) 1 (10) 0.171
 Low-flow nasal cannula, n (%) 4 (29) 7 (70) 0.095
 Mechanical ventilation, n (%) 9 (64) 3 (30) 0.214
 Extracorporeal membrane oxygenation, n (%) 1 (7) 0 1
 CP transfusion
  Low dose, n (%) 9 (69)
  High dose, n (%) 4a (31)
  Initial transfusion time, mean ± SE, db 20.7 ± 3.6
Mortality
 7-day mortality, n (%)c 1 (7) 0 1
 28-day mortality, n (%)d 3 (21) 1 (10) 0.615
Radiological alleviation of lesions
 7-day alleviation proportion, n (%)c 5 (36) 2 (20) 0.653
 28-day alleviation proportion, n (%)d 12 (86) 5 (50) 0.085
  1. CP convalescent plasma, SE stand error
  2. aPatient No. 1 was excluded from the analysis since she could not finish the high-dose therapeutic scheme due to the death of aggressive progression before the second dose
  3. bDays from hospital admission to initial transfusion of CP
  4. cWithin 7 days after initial CP transfusion for patients received CP or treatment without CP in ICU
  5. dWithin 28 days after initial CP transfusion for patients received CP or treatment without CP in ICU